Immunotherapy with NK cells: recent developments in gene modification open up new avenues

Area of Science:

• Immunotherapy
• Cellular Therapy
• Oncology

Background:

• Chimeric antigen receptor (CAR)-T cell therapies have demonstrated significant clinical success.
• CAR-T cell toxicities, including cytokine release syndrome and neurotoxicity, necessitate alternative approaches.
• Natural killer (NK) cells are emerging as promising candidates for immunotherapy due to their safety profile.

Purpose of the Study:

• To review the current research landscape of CAR-NK cells.
• To summarize the clinical applications and developmental potential of CAR-NK cell therapy.
• To highlight the advantages of CAR-NK cells over CAR-T cells.

Main Methods:

• Literature review of preclinical and clinical studies on CAR-NK cells.
• Analysis of ongoing clinical trials involving CAR-NK cell therapy.
• Comparative assessment of CAR-NK and CAR-T cell mechanisms and outcomes.

Main Results:

• CAR-NK cells possess dual killing mechanisms (CAR-dependent and -independent).
• CAR-NK cells exhibit a favorable safety profile with reduced side effects compared to CAR-T cells.
• The number of clinical trials for CAR-NK cells is rapidly increasing, with 19 studies currently active globally.

Conclusions:

• CAR-NK cells represent a promising next-generation immunotherapy with dual-action capabilities.
• The reduced toxicity of CAR-NK cells positions them as a potentially safer alternative to CAR-T cells.
• Further research and clinical development of CAR-NK cells are warranted to fully realize their therapeutic potential.